| Literature DB >> 33145045 |
Roberto Cherchi1, Giulia Grimaldi1, Matteo Pinna-Susnik1, Laura Riva1, Sabrina Sarais1, Massimiliano Santoru1, Roberto Perra2, Roberto Allieri3, Giuseppe S Porcu4, Sonia Nemolato4, Antonella Mameli5, Federica Loi6, Paolo A Ferrari1.
Abstract
BACKGROUND: Surgical lung biopsy for interstitial lung disease (ILD) is traditionally performed through video-assisted thoracic surgery (VATS) and general anesthesia (GA). The mortality and morbidity rates associated with this procedure are not negligible, especially in patients with significant risk factors and respiratory impairment. Based on these considerations, our center evaluated a safe non-intubated VATS approach for lung biopsy performed in ILD subjects.Entities:
Keywords: Awake surgery; interstitial lung disease (ILD); non-intubated video-assisted thoracic surgery (NIVATS); surgical lung biopsy (SLB); tubeless anesthesia
Year: 2020 PMID: 33145045 PMCID: PMC7578489 DOI: 10.21037/jtd-20-1551
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1Uniportal NIVATS procedure for lung biopsy. Division of Thoracic Surgery, “A. Businco” Oncology Hospital, Cagliari (IT). NIVATS, non-intubated video-assisted thoracic surgery.
Baseline characteristics and post-operative outcomes of patients who underwent NIVATS uniportal lung biopsy for undetermined ILD
| Variable | ILD patients (n=99) |
|---|---|
| Sex, n [%] | |
| Male | 73 [74] |
| Female | 26 [26] |
| Age (years), mean [SD] | 66 [10] |
| Smoke, n [%] | |
| Active | 8 [8] |
| Ex-smokers | 61 [62] |
| No-smokers | 30 [30] |
| Body mass index (score), mean (SD) | 27.0 (4.7) |
| Charlson comorbidity (score), mean (SD) | 4.1 (1.9) |
| American Society of Anesthesiologists (score), mean (SD) | 2.1 (0.5) |
| Forced vital capacity percentage (FVC%), mean (SD) | 84.9 (25.5) |
| Forced expiratory volume in 1st second percentage (FEV1%), mean (SD) | 86.3 (23.1) |
| Diffusing capacity for carbon monoxide percentage (DLCO%), mean (SD) | 59.6 (18.3) |
| Post-operative complications, n [%] | |
| Yes | 9 [9] |
| Not | 90 [91] |
| Decubitus, n [%] | |
| Left side | 48 [48] |
| Right side | 43 [43] |
| Supine | 8 [8] |
| Surgical operating room time (min), mean (SD) | 42.5 (20.2) |
| Biopsy site, n [%] | |
| Right lower lobe (RLL) | 27 [27] |
| Left upper lobe (LUL) | 28 [28] |
| Left lower lobe (LLL) | 16 [16] |
| Right upper lobe (RUL) | 11 [11] |
| Middle lobe (ML) | 4 [4] |
| LUL + LLL | 5 [6] |
| RLL + ML | 2 [2] |
| RUL + RLL | 6 [6] |
| Number of lung biopsies, mean (SD) | 1.2 (0.4) |
| Average specimen length (centimeters), mean (SD) | 3.4 (1.4) |
| Feasibility, n [%] | |
| Easy | 53 [54] |
| Feasible (e.g., only one biopsy) | 33 [33] |
| Difficult (e.g., deeper sedation required) | 13 [13] |
| Pleural adhesions, n [%] | 24 [24] |
| Intra-operative complications, n [%] | |
| Minor bleeding | 1 [1] |
| Psychomotor agitation | 1 [1] |
| Respiratory impairment | 2 [2] |
| Global operating room time (min), mean (SD) | 73.7 (34.3) |
| Chest tube size (French), n [%] | |
| 19 | 1 [1] |
| 21 | 31 [31] |
| 28 | 67 [68] |
| Chest tube indwelling time (days), median [I–III quartile] | 1 [0–1] |
| Chest tube effusion (ml), median [I–III quartile] | 50 [15–100] |
| Post-operative complications (Clavien-Dindo grade I), n [%] | 9 [9] |
| Post-operative length of stay (days), mean (SD) | 1.3 (0.9) |
| Readmission, n [%] | 3 [3] |
| 30-day patient survival, n [%] | 98 [99] |
| Post-operative diagnosis, n [%] | 97 [98] |
| Histopathology diagnosis, n [%] | |
| Usual interstitial pneumonia | 60 [61] |
| Probable usual interstitial pneumonia | 1 [1] |
| Indeterminate for usual interstitial pneumonia | 9 [9] |
| Alternative diagnosis | 27 [27] |
| Not diagnostic | 2 [2] |
NIVATS, non-intubated video-assisted thoracic surgery; ILD, interstitial lung disease.
Figure 2Main baseline characteristics and post-operative outcomes of patients who underwent NIVATS uniportal lung biopsy. NIVATS, non-intubated video-assisted thoracic surgery.
Descriptive statistics of peri-operative anesthesia and analgesia management in NIVATS uniportal lung biopsy for undetermined ILD
| Variable | ILD patients (n=99) |
|---|---|
| Conversion to general anesthesia, n [%] | 0 [0] |
| Intra-operative peripheral oxygenation (%), mean (SD) | 97.2 (2.2) |
| Intra-operative O2 supply (L/min), mean (SD) | 3.6 (1.5) |
| Intra-operative anesthesia medications, n [%] | |
| Midazolam | 9 [9] |
| Fentanyl | 2 [2] |
| Remifentanil | 1 [1] |
| Propofol | 1 [1] |
| Midazolam + fentanyl | 9 [9] |
| Midazolam + remifentanil | 15 [15] |
| Remifentanil + propofol | 3 [3] |
| Midazolam + fentanyl + remifentanil | 30 [30] |
| Midazolam + fentanyl + propofol | 1 [1] |
| Midazolam + remifentanil + propofol | 13 [13] |
| Midazolam + fentanyl + remifentanil + propofol | 15 [15] |
| Locoregional analgesia, n [%] | |
| Paravertebral catheter | 4 [4] |
| Intercostal nerve block | 38 [38] |
| None | 57 [58] |
| Post-operative analgesia supply, n [%] | 57 [57] |
| Paracetamol supply | 42 [74] |
| Nonsteroidal anti-inflammatory drug supply | 52 [91] |
| Mean Numeric Pain Rate Scale (score), mean (SD) | 1.13 (0.82) |
Data is represented as mean (SD) or number [%], based on variable distribution. NIVATS, non-intubated video-assisted thoracic surgery; ILD, interstitial lung disease.
Pearson’s correlation coefficients between independent variables considered in the study
| Variable | ID | Global OR time (min) | Surgical OR time (min) | pLOS (days) | BMI | Age (years) | FEV1% | FVC% | Charlson comorbidity (score) | Chest tube total effusion (mL) | Chest tube indwelling time (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | – | – | – | – | – | – | – | – | – | – | – |
| Global OR time (min) | −0.5864 (P<0.0001)* | – | – | – | – | – | – | – | – | – | – |
| Surgical OR time (min) | −0.3033 (P=0.0023)* | 0.5834 (P<0.0001)* | – | – | – | – | – | – | – | – | – |
| pLOS (days) | 0.0459 (P=0.6499) | 0.0835 (P=0.4115) | 0.0254 (P=0.8028) | – | – | – | – | – | – | – | – |
| BMI | −0.0401 (P=0.7985) | 0.2156 (P=0.0321)* | 0.2963 (P=0.0029)* | – | – | – | – | – | – | – | – |
| Age (years) | 0.0177 (P=0.8614) | 0.0191 (P=0.8508) | 0.1221 (P=0.2286) | −0.2834 (P=0.0043)* | 0.1937 (P=0.0534) | – | – | – | – | – | – |
| FEV1% | −0.0542 (P=0.6160) | −0.1633 (P=0.1285) | −0.2237 (P=0.0372)* | −0.2282 (P=0.0325)* | −0.0041 (P=0.9698) | 0.2392 (P=0.0248) | – | – | – | – | – |
| FVC% | −0.0575 (P=0.5948) | −0.1151 (P=0.2856) | −0.2161 (P=0.0444)* | −0.2487 (P=0.0195)* | −0.0532 (P=0.6624) | 0.0578 (P=0.5930) | 0.8953 (P<0.0001)* | – | – | – | – |
| Charlson comorbidity (score) | 0.0154 (P=0.8790) | 0.0035 (P=0.9722) | 0.0437 (P=0.6676) | −0.1887 (P=0.0601) | 0.0028 (P=0.9797) | 0.5682 (P<0.0001)* | −0.0150 (P=0.8900) | −0.0833 (P=0.4403) | – | – | – |
| Chest tube total effusion (mL) | 0.0120 (P=0.9058) | 0.1678 (P=0.0915) | −0.0139 (P=0.8916) | 0.6147 (P<0.0001)* | −0.2669 (P=0.0073)* | −0.1024 (P=0.3108) | −0.2192 (P=0.0402)* | −0.2289 (P=0.0319)* | −0.0730 | – | – |
| Chest tube indwelling time (days) | 0.2191 (P=0.0285) | −0.0308 (P=0.7610) | −0.1181 (P=0.0622) | 0.8064 (P<0.0001)* | −0.1369 (P=0.1744) | −0.2381 (P=0.0171)* | −0.2203 (P=0.0392)* | −0.2205 (P=0.0390)* | −0.1313 | 0.6616 | – |
*, statistically significant correlation coefficient and P values. ID, progressive and subsequent number attributed to each patient upon admission; OR, operating room; pLOS, post-operative length of stay; BMI, body mass index; FEV1%, forced expiratory volume in the 1st second percentage; FVC%, forced volume capacity percentage.
Results of linear regression model aimed at estimating the distribution of the different surgical times and in-hospital stay
| Variable | Coeff. | 95% CI | P value |
|---|---|---|---|
| A) Surgical OR time (min) | |||
| ID (patients enrolment progression) | −0.204 | −0.337, −0.071 | 0.003 |
| BMI | 1.270 | 0.446, 2.094 | 0.003 |
| Adhesions (yes) | 12.173 | 3.082, 21.263 | 0.009 |
| FEV1% | −0.202 | −0.368, −0.037 | 0.017 |
| B) Global OR time (min) | |||
| ID (patients enrolment progression) | −0.435 | −0.659, −0.212 | <0.0001 |
| BMI | 1.689 | 0.582, 2.797 | 0.003 |
| Remifentanil (alone) | −29.569 | −44.946, −14.192 | <0.0001 |
| C) pLOS (days) | |||
| ID (patients enrolment progression) | −0.005 | −0.008, −0.001 | 0.005 |
| BMI | 0.014 | 0.008, 0.036 | 0.214 |
| Chest tube indwelling time (days) | 0.885 | 0.741, 1.030 | <0.0001 |
| Clavien-Dindo complication (yes) | 0.868 | 0.492, 1.245 | <0.0001 |
| Charlson comorbidity (score) | −0.040 | −0.092, −0.010 | 0.115 |
A) results of the linear regression model for surgical OR time as the outcome; B) results of linear regression model for global OR time as the outcome; C) results of linear regression model for pLOS as the outcome. Data is presented as regression coefficient (β), 95% confidence interval (95% CI) and P value. OR, operating Room; pLOS, post-operative length of stay; BMI, body mass index; FEV1%, forced expiratory volume in the 1st second percentage.
Post-operative outcomes between patients treated with intercostal blockage (group A) and local anesthesia only (group B)
| Variable | Group A (n=38) | Group B (n=57) | P value |
|---|---|---|---|
| Surgical OR time (min), mean (SD) | 37.71 (12.30) | 46.07 (23.95) | 0.051 |
| Global OR time (min), mean (SD) | 59.21 (18.44) | 79.17 (37.12) | 0.003 |
| pLOS (days), mean (SD) | 1.16 (0.63) | 1.47 (1.05) | 0.101 |
| NPRS (score), mean (SD) | 1.34 (0.85) | 1.05 (0.76) | 0.087 |
| Post-operative rescue analgesia, n (%) | 20 (52.6) | 33 (57.9) | 0.613 |
OR, operating room; pLOS, post-operative length of stay; NPRS, Numeric Pain Rate Scale.
Figure 3Global operating room (OR) length of stay and surgical operating time comparison between patients treated with or without intercostal nerve blockage anesthesia.
Post-operative outcomes between patients drained with small chest tubes (19 or 21 French) and large chest tubes (28 French)
| Variable | Small CT (n=32) | Large CT (n=67) | P value |
|---|---|---|---|
| pLOS (days), mean (SD) | 1.56 (1.16) | 1.21 (0.81) | 0.082 |
| NPRS (score), mean (SD) | 1.06 (0.71) | 1.17 (0.87) | 0.511 |
| Post-operative complications, n (%) | 4 (12.5) | 5 (7.5) | 0.415 |
pLOS, post-operative length of stay; NPRS, Numeric Pain Rate Scale.
Figure 4Histopathologic hallmark of usual interstitial pneumonia (UIP). (A) HE 10×. Architectural remodelling as a result of patchy dense fibrosis in peripheral area inside the lobule and the perivenular area. Microscopic honeycombing cysts noted; (B) HE 40×. The fibroblastic focus consists of fibroblasts and myofibroblasts and are covered by type II pneumocytes or cuboidal metaplastic epithelia. Histopathology Department, “A. Businco” Oncology Hospital, Cagliari (IT).